Event info
Date:06 May
Time:17:00-20:00
Venue:Medicon Valley Alliance, Copenhagen S

MVA R&D Network meeting

Welcome to Medicon Valley Alliance R&D Network and our 3rd meeting!

What can R&D learn from orphan drug development:
– The use of AI to find the right patients
– Working closely with stakeholders

Finding the right treatment for the right patient is one major challenge within R&D. The challenges inherent in drug development in rare diseases has enforced stakeholders in this field in pioneering new ways during their R&D.

Medicon Valley Alliance, together with one of our members – Zealand Pharma – welcomes you to the MVA R&D Network and our 3rd meeting where we will discuss lessons learned from drug development in rare diseases and how this could be applied to all drug development. Aspects like how to implement AI and how to relate to and interact with the ever-changing stakeholder landscape will be highlighted.

Date: 6 May, 2019
Time: 17:00 – 20:00
Host:Zealand Pharma A/S
Venue:Medicon Valley Alliance, Auditorium, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen
Cost:Free of charge for MVA members

Sign up

The network
Medicon Valley Alliance R&D Network – an interdisciplinary network for C-level R&D executives (CSOs, CMOs, VPs), university professors and PIs, and top-level managers in the hospital sector. The objective of the network is to strengthen collaboration and knowledge-sharing to stimulate that great science turns into successful innovations for the benefit of patients and society. The network is scheduled to meet twice a year.
The network is free of charge and is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate whether joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the Medicon Valley Alliance R&D Network.

Program
Moderator: Anders Hinsby, CEO, Orphazyme

17.00 – 17.30Registration, networking and a bite to eat
17.30 – 17.40Welcome 
Petter Hartman, CEO, Medicon Valley Alliance
Camilla Westergaard Borgen, Commercial Development Director, Zealand Pharma A/S
17.40-18.25The use of AI to find the right patients
17.40Deploying predictive analytics for precision patient and provider finding

Oodaye Shukla, Chief Data & Analytics Officer, HVH Precision Analytics, Pennsylvania, US
18.10AI at Lund University – ongoing activities and opportunities for academia-industry interaction

Sonja Aits, Associate Senior Lecturer, Cell Death and Lysosomes Group, Dept. of Experimental Medical Science, Lund University
18.25-19.05Working closely with stakeholders
18.25Early engagement with regulators to improve drug development

Steffen Thirstrup, Director, NDA Regulatory Advisory Board, former CHMP member and Division Head at the Danish Medicines Agency
18.45 Why involve patients in medical research? 

Jeanette Andersen, EUPATI Patient Expert & Chair, Lupus Europe
19.05-19.25Panel discussion
Oodaye Shukla, Chief Data & Analytics Officer, HVH Precision Analytics, Pennsylvania, US
Sonja Aits, Associate Senior Lecturer, Cell Death and Lysosomes Group, Dept. of Experimental Medical Science, Lund University
Steffen Thirstrup, Director, NDA Regulatory Advisory Board, former CHMP member and Division Head at the Danish Medicines Agency
Jeanette Andersen, EUPATI Patient Expert & Chair,Lupus Europe
19.25-19.30Concluding remarks
Camilla Westergaard Borgen, Commercial Development Director Zealand Pharma A/S
19.30 – 20.00Networking & refreshments

For more information please contact Senior Project Manager Helen Pettersson: hp@mva.org

 

Host Sponsors
 

 

MVA R&D Network is managed byIn collaboration with